What are the contraindications to the use of Quizartinib? Who is not suitable to use this medicine?

Quizartinib is a targeted drug mainly used to treat patients with acute myeloid leukemia (AML) who have FLT3 mutations. FLT3 mutation is a common gene mutation that is often associated with poor prognosis in AML patients. Quizartinib plays an anti-tumor role by inhibiting the kinase activity of the FLT3 receptor and inhibiting the proliferation of tumor cells. Although Quizartinib is highly effective in treating certain types of leukemia, it does have some contraindications, and certain patient groups may be at higher risk or experience adverse effects when using the drug. The following details the contraindications of Quizartinib and the groups who are not suitable for using this drug.

1. Patients known to be allergic to quizartinib or its components

One of the contraindications to Quizartinib is patients who are allergic to the drug or any of its components. Allergic reactions may include rash, itching, shortness of breath, facial swelling, throat swelling, wheezing, etc. Patients should avoid using this medicine if they know they are allergic to any component of this medicine before taking this medicine. This type of allergic reaction may not only cause discomfort, but may also trigger severe anaphylactic shock, which is life-threatening. Therefore, before using quizartinib, patients must inform their doctor if they have any history of drug allergies, especially to targeted drugs or chemotherapy drugs.

2. Patients with severe heart disease

Quizatinib may affect cardiac function when used, in particular, it may prolong the QT interval and increase the risk of serious arrhythmias. QT Prolonged QT interval is an electrocardiogram abnormality that may lead to serious arrhythmias, including torsade de pointes and ventricular fibrillation. Quizartinib should be avoided in patients with known cardiac disease, such as heart failure, cardiomyopathy, cardiac arrhythmia (especially a history of prolongation of the QT interval), electrolyte abnormalities (such as hypokalemia or hypocalcemia), or if they are taking drugs that may prolong the QT interval. Such patients may face a higher risk of cardiac side effects when using quizartinib and must use it under strict supervision by a doctor.

3. Pregnant and lactating women

Quizartinib is a potentially teratogenic drug and is therefore contraindicated in pregnant women. Quizartinib may be passed to the fetus across the placenta, increasing the risk of birth defects or other developmental abnormalities in the fetus. Although some teratogenicity has been shown in animal studies, the exact effects in humans are not fully understood. Pregnant women should avoid using quizartinib during pregnancy due to the drug's potential risk to the fetus.

In addition, it is not fully known whether Quizartinib is excreted in breast milk, so its use should also be avoided in breastfeeding women. If the patient is breastfeeding, he should consider stopping breastfeeding or discontinuing the use of quizartinib, and choose the best option according to the doctor's advice. Women should avoid becoming pregnant and use effective contraception while taking quizartinib.

4. Patients with hepatic insufficiency

Quizartinib is primarily metabolized by the liver; therefore, patients with hepatic impairment require special caution when using this drug. For patients with impaired liver function, the metabolism of quizartinib may be affected, and the concentration of the drug in the body may increase, leading to an increase in toxic reactions or adverse reactions. Therefore, the use of quizartinib is generally not recommended for patients with severely impaired liver function, such as hepatitis, cirrhosis, etc. In this case, patients should choose other treatment options or adopt more stringent dose adjustment and monitoring measures based on the doctor's advice.

Use of quizartinib may require dose adjustment in patients with moderate hepatic impairment. Patients need to check their liver function regularly during treatment to ensure the safety and effectiveness of the drug. If there are signs of abnormal liver function, treatment should be stopped promptly and the medication regimen should be adjusted according to the situation.

5. Patients with severe renal insufficiency

Quizartinib is also primarily excreted via the kidneys; therefore, special caution is required when using quizartinib in patients with renal insufficiency. Although patients with renal impairment generally do not experience significant changes in drug clearance due to mild or moderate renal impairment, drug accumulation of quizartinib in patients with severe renal impairment may result in increased adverse effects. Therefore, the use of quizartinib is not recommended in patients with severe renal impairment. If a patient has kidney function problems, the doctor may choose other treatments or adjust the dosage based on specific kidney function.

Quizartinib, as a targeted therapy, has significant therapeutic effects, but it is not suitable for all patients. Quizartinib should be avoided in patients who are allergic to this drug or its components, patients with serious heart disease, pregnant and breastfeeding women, patients with hepatic impairment, and patients with severe renal impairment. Before using Quizartinib, patients should inform their doctor in detail about their medical history and current health status so that the doctor can make the most appropriate treatment decision. In addition, when using quizartinib, patients should undergo regular examinations to monitor possible side effects and drug reactions to ensure the safety and effectiveness of the treatment.

Reference materials:https://go.drugbank.com/drugs/DB12874